A
A
    Global websites
    Local websites
    language header world map

    Regulations

    Download as PDF

    Colorado law requires prescription drug manufacturers to disclose in writing to Colorado prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the product listed below. 

    NDCargenx ProductDosage FormStrengthUnit SizePrice per mgWholesale Acquisition Cost*
    73475-3041-5VYVGART (efgartigimod alfa-fcab)Solution in Vial Injection400 mg in 20 mL (20 mg/ml) Single Dose VialSingle Use Vial$15.17/mg$6,190.38 as of March 8, 2024

    2 or 3 vials per dose (weight based)

     

    The price to acquire the product listed may differ from the WAC price listed. How much a patient will pay will depend on the patient’s insurance coverage. To find out the exact cost of a prescription, patients should contact their health insurance company. 

    Colorado law also requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. Colorado defines “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” There are currently no generic prescription drugs in the same “therapeutic class” (based on the definition of “therapeutic class” under Colorado law) as the listed argenx product. 

    *Pricing as of February 17, 2023. The pricing information disclosed above represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers. WAC does not represent actual transaction prices and does not include other discounts, rebates or reductions in price. Pricing information listed does not imply safety or efficacy of the products, and no comparisons should be made.  

    VYVGART is a registered trademark of argenx. ©2023 argenx. All rights reserved.

    US-EFG-21-00374 v5 06/2023

    Download as PDF

    Colorado law requires prescription drug manufacturers to disclose in writing to Colorado prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing. This disclosure provides the WAC price for the product listed below.

    NDCargenx ProductDosage FormStrengthUnit SizePrice per mgWholesale Acquisition Cost*
    73475-3102-3VYVGART Hytrulo (efgartigimod alfa and hyaluronidase -qvfc)Solution in Vial Injection1,008 mg efgartigimod alfa and 11,200 Units hyaluronidase per 5.6 mL (180 mg/2,000 Units per mL)Single Use Vial$15.65/mg$15,773.00 as of June 20, 2023

    1 vial per dose

     

    The price to acquire the product listed may differ from the WAC price listed. How much a patient will pay will depend on the patient’s insurance coverage. To find out the exact cost of a prescription, patients should contact their health insurance company.

    Colorado law also requires manufacturers to provide the names of generic prescription drugs from the same “therapeutic class” as the marketed products. Colorado defines “therapeutic class” as “a group of similar drugs that have the same or similar mechanisms of action and are used to treat a specific condition.” There are currently no generic prescription drugs in the same “therapeutic class” (based on the definition of “therapeutic class” under Colorado law) as the listed argenx product.

    *Pricing as of June 20, 2023. The pricing information disclosed above represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers. WAC does not represent actual transaction prices and does not include other discounts, rebates or reductions in price. Pricing information listed does not imply safety or efficacy of the products, and no comparisons should be made. 

    VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx. ©2023 argenx. All rights reserved.

    US-ESC-23-00218 v1 06/2023

    Download as PDF

    Connecticut law requires prescription drug manufacturers to disclose in writing to Connecticut prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing, as required by Connecticut House Bill No.6669. This disclosure provides the WAC price for the product listed below.

    NDCargenx ProductDosage FormStrengthUnit SizePrice per mgWholesale Acquisition Cost*
    73475-3041-5VYVGART (efgartigimod alfa-fcab)Solution in Vial Infusion400 mg in 20 mL (20 mg/ml) Single Dose VialSingle Use Vial$15.17/mg$6,190.38 as of March 8, 2024
    2 or 3 vials per dose (weight based)

     

    The price to acquire the product listed may differ from the WAC price listed. How much a patient will pay will depend on the patient’s insurance coverage. To find out the exact cost of a prescription, patients should contact their health insurance company.

    Connecticut law also requires manufacturers to provide information on the variation efficacy of the drug marketed to different racial and ethnic groups if such information is available. This information is not currently available for the product(s) listed above.

    *Pricing as of February 17, 2023. The pricing information disclosed above represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers. WAC does not represent actual transaction prices and does not include other discounts, rebates or reductions in price. Pricing information listed does not imply safety or efficacy of the products, and no comparisons should be made.

    VYVGART is a registered trademark of argenx. ©2023 argenx. All rights reserved.

    US-EFG-23-00035 v111/2023

    Download as PDF

    Connecticut law requires prescription drug manufacturers to disclose in writing to Connecticut prescribers the Wholesale Acquisition Cost (“WAC”) of marketed drugs when engaging in prescription drug marketing, as required by Connecticut House Bill No.6669. This disclosure provides the WAC price for the product listed below.

    NDCargenx ProductDosage FormStrengthUnit SizePrice per mgWholesale Acquisition Cost*
    73475-3102-3VYVGART Hytrulo (efgartigimod alfa and hyaluronidase -qvfc)Solution in Vial Injection1,008 mg efgartigimod alfa and 11,200 Units hyaluronidase per 5.6 mL (180 mg/2,000 Units per mL) Single Dose VialSingle Use Vial$15.65/mg$15,773.00 as of June 20, 2023

    1 vial per dose

     

    The price to acquire the product listed may differ from the WAC price listed. How much a patient will pay will depend on the patient’s insurance coverage. To find out the exact cost of a prescription, patients should contact their health insurance company.

     

    Connecticut law also requires manufacturers to provide information on the variation efficacy of the drug marketed to different racial and ethnic groups if such information is available. This information is not currently available for the product(s) listed above.

    *Pricing as of June 20, 2023. The pricing information disclosed above represents the WAC price, which represents the manufacturer’s published catalog or list price for a drug product to wholesalers as reported to third-party drug pricing publishers. WAC does not represent actual transaction prices and does not include other discounts, rebates or reductions in price. Pricing information listed does not imply safety or efficacy of the products, and no comparisons should be made.

    VYVGART is a registered trademark of argenx. VYVGART Hytrulo is a trademark of argenx. ©2023 argenx. All rights reserved.

    US-ESC-23-00337v111/2023